Share:
BEIJING and BOSTON, Dec. 23, 2020 (GLOBE NEWSWIRE) 1Globe Capital LLC ( 1GlobeCap ), a principal and long-term shareholder of Sinovac Biotech (NASDAQ:SVA) ( Sinovac ), has reached agreement with the Securities and Exchange Commission ( SEC ) to end investigation of its 13D form compliance.
During this critical phase of vaccine and therapeutics development for the ongoing pandemic, 1GlobeCap felt it was important to focus on its many projects, which include the development of COVID-19 therapeutics and vaccines. For this reason, 1GlobeCap decided to accept a SEC settlement offer, in which 1GlobeCap neither admitted nor denied SEC findings.
Following Sinovac s annual general meeting ( AGM ) on February 6